Salta al contenuto principale
Passa alla visualizzazione normale.

CHIARA RIZZO

The role of bDMARDs in idiopathic inflammatory myopathies: A systematic literature review

  • Autori: Grazzini, Silvia; Rizzo, Chiara; Conticini, Edoardo; D'Alessandro, Roberto; La Barbera, Lidia; D'Alessandro, Miriana; Falsetti, Paolo; Bargagli, Elena; Guggino, Giuliana; Cantarini, Luca; Frediani, Bruno
  • Anno di pubblicazione: 2023
  • Tipologia: Review essay (rassegna critica)
  • OA Link: http://hdl.handle.net/10447/620265

Abstract

: Idiopathic inflammatory myopathies (IIM) are a group of different conditions typically affecting striate muscle, lung, joints, skin and gastrointestinal tract. Treatment typically relies on glucocorticoids and synthetic immunosuppressants, but the occurrence of refractory, difficult to treat, manifestations, may require more aggressive treatment, borrowed from other autoimmune diseases, including biologic disease modifying drugs (bDMARDs). In this regard, we conducted a systemic literature review in order to depict the current evidence about the use of bDMARDs in IIM. A total of 78 papers, published during the last 21 years, were retrieved. The majority of patients was treated with TNF-α inhibitors, whose effectiveness was assessed particularly in recalcitrant striate muscle, skin and joints involvement. Rituximab, whose evidence is supported by a large number of real-life studies and trials, seems to be an excellent option in case of ILD and anti-synthetase syndrome, while Tocilizumab, despite not meeting primary and secondary endpoints in a recently published clinical trial, proved its effectiveness in rapidly progressing ILD. Similarly, Abatacept, studied in a phase IIb clinical trial with conflicting evidence, was reported to be effective in some case reports of refractory dermatomyositis. Less data exist for anti-IL1 and anti-IL23 agents, which were employed particularly for inclusion body myositis and severe skin disease, respectively. This study provides an organ-focused assessment of bDMARDs in IIM, which display encouraging results in the treatment of refractory subsets of disease.